At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
FB825, FB825-15D11, Anti-CemXdrug
Likely dose
FB825, FB825-15D11, Anti-CemX 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating FB825, FB825-15D11, Anti-CemX for Atopic Dermatitis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesTaiwan
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedNov 2018
Primary CompletionJan 2019
Study CompletionSep 2019
TodayJul 2026
First PostedNov 29, 2018
Enrollment StartJul 3, 2017
Primary CompletionJan 28, 2019
Study CompletionSep 19, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.6 years ago
Interventions
FB825, FB825-15D11, Anti-CemXdrug
Pharmaceutical form: 20mg/ml solution Route of administration: IV